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The primary goal of combination highly active antiretroviral therapy (HAART) is to achieve full and long-term suppression of human immunodeficiency virus type 1 (HIV-1) RNA plasma viral load (hereafter, ''viral load'') at all stages of HIV disease, even among those infected with multipledrug-resistant HIV (1) . HAART can predictably suppress viral replication, which in turn allows immune reconstitution to take place, reduces the emergence of any resistance and, most importantly, reduces acquired immunodeficiency syndrome (AIDS)-related morbidity and mortality (1) (2) (3) (4) (5) .
Although a majority of patients who initiate HAART are expected to derive a full treatment response with sustained undetectable viral load and consequent CD4 cell count recovery, there are a number of patients who will experience virologic failure, including failure to suppress or viral load rebound (6) . Ongoing viral replication under drug pressure is particularly problematic as it promotes the emergence of drug resistance, which in turn compromises future treatment options (7) (8) (9) (10) (11) . Furthermore, resistant virus can be transmitted, giving rise to primary resistant HIV cases (12) (13) (14) . Recent expansion of available antiretroviral agents has dramatically enhanced the rate of therapeutic success among treatment-naïve and -experienced patients. Full suppression of viral replication has therefore become a realistic goal even in the setting of multiclass-resistant HIV infection (2, (15) (16) (17) .
Given the recent evolution of therapeutic trends, it is important to understand the current epidemiology of multiclassresistant HIV infection. It is clear that individuals who were treated in the pre-HAART era were often exposed to sequential, partially suppressive regimens, which promoted the emergence of multiclass-resistant HIV infection. The frequency and determinants of multiclass-resistant HIV infection in the modern HAART era are less well characterized.
Therefore, we undertook the present study to characterize the epidemiology of antiretroviral multiclass resistance in the modern HAART era. We also sought to calculate the incidence rate of multiclass drug resistance among HAART-naïve patients enrolled in a province-wide HAART distribution program in British Columbia, Canada, from 2000 to 2007.
MATERIALS AND METHODS

Study population
The present study was conducted within the HAART Observational Medical Evaluation and Research Cohort, which is a prospective observational cohort of all antiretroviralnaïve patients aged 18 years or older initiating HAART in British Columbia, and has been described in detail elsewhere (2). The cohort is followed in a unique environment characterized by universal free medical care, including free medical care, laboratory monitoring, and antiretroviral drugs. The antiretroviral drugs are centrally distributed by the British Columbia Centre for Excellence in HIV/AIDS according to the Centre's treatment guidelines, which have remained consistent with those put forward by the International AIDS Society-United States of America (''IAS-USA'') since the summer of 1996 and until the most recent guidelines released in 2008 (1) . This allows for a unique opportunity to study therapeutic outcomes from HIV treatment in a setting where all financial barriers to HIV/AIDS and other medical care are eliminated.
Eligible study participants started HAART consisting of 2 nucleoside reverse transcriptase inhibitors (NRTIs) or a NRTI plus a nucleotide reverse transcriptase inhibitor (NtRTI) as backbone, plus either a nonnucleoside reverse transcriptase inhibitor (NNRTI) or a protease inhibitor boosted with 400 mg/day of ritonavir or an unboosted protease inhibitor. Participants started treatment between January 1, 2000, and June 30, 2006, and were followed until June 30, 2007. Note that our patients' regimens, over the study period, have changed because of the availability of new antiretroviral drugs through compassionate release, studies, and expanded access programs. Figure 1 is similarly posted.)
Laboratory monitoring
The Centre's therapeutic guidelines recommend monitoring the efficacy of HAART with longitudinal measurement of viral load and CD4 cell count (3-4 times per year). Viral loads are determined at a single laboratory by using the Roche Amplicor Monitor assay (Roche Diagnostics, Laval, Quebec, Canada) with the ultrasensitive adaptation. CD4 cell counts are measured by flow cytometry, followed by fluorescent monoclonal antibody analysis (Beckman Coulter, Inc., Mississauga, Ontario, Canada). Resistance testing is recommended at baseline and at virologic failure (i.e., failure to suppress or viral load rebound). Testing is performed at a single laboratory on fresh or stored viral load samples extracted manually or automatically with guanidinium-based buffer, followed by ethanol washes. Protease genes and reverse-transcriptase genes were amplified from plasma HIV-1 RNA by nested reverse-transcriptase polymerase chain reaction, as described elsewhere (2) . Polymerase chain reaction products are sequenced in both the 5' and 3' directions by using an ABI automated sequencer (Applied Biosystems, Foster City, California), and a consensus sequence is generated. Results of the genotyping analysis are reported here as amino acid changes in the HIV protease genes and reverse transcriptase genes with respect to a wild-type reference sequence (HIV HXB2; GenBank accession number K03455).
For analytical purposes, samples were assigned to 1 of 3 resistance categories on the basis of a list of important resistant mutations in the reverse transcriptase and protease genes (18) . Antiretroviral resistance mutations were classified in one of the following categories: NNRTI, NRTI/ NtRTI, and protease inhibitor mutations (referring to mutations associated with decreased susceptibility to the nonnucleoside reverse transcriptase inhibitors, the nucleoside/ nucleotide reverse transcriptase inhibitors, and the protease inhibitors, respectively). Because genotyping does not yield consistently successful results for samples with low viral load and based on the different genotypic resistance tests used throughout our study, samples with a viral load of <1,000 copies/mL tested prior to 2002 and samples with a viral load of <250 copies/mL tested in 2002 and later were not systematically genotyped and were assumed to harbor no resistance mutations.
Outcome measure and covariates
The primary endpoint in this analysis was antiretroviral multiclass resistance defined as the accumulation of resistance to 2 classes or to all 3 classes of antiretroviral drugs, within the NRTI/NtRTI, NNRTI, and protease inhibitor drug classes. Baseline covariates included the following: age, gender, CD4 cell count, viral load (log 10 transformed), HAART regimen class (boosted protease inhibitor, unboosted protease inhibitor, NNRTI), and history of injection drug use. The CD4 cell count and viral load were also reported at the time of the emergence of multiclass resistance, and we included these variables as changes in viral load and in CD4 cell count from baseline to the time of emergence of multiclass resistance or censoring. All measurements were taken before the assessment of multiclass resistance for those with multiclass resistance or at the end of follow-up, death, or study end date for those who did not develop multiclass resistance. In light of the ever-increasing number of HIV/AIDS therapies, it became impractical to account for each and every therapy during follow-up. Instead, we used the cumulative number of therapy changes up to the time of the emergence of multiclass resistance. Allowable changes included NNRTI 4 unboosted protease inhibitor, NNRTI 4 boosted protease inhibitor, NNRTI 4 multiple protease inhibitor, unboosted protease inhibitor 4 boosted protease inhibitor, unboosted protease inhibitor 4 multiple protease inhibitor, and boosted protease inhibitor 4 multiple protease inhibitor.
Estimates of adherence were obtained at the first year since HAART initiation and based on prescription refills, as previously described (2, 4, 6) . In brief, adherence was estimated by dividing the number of months of medications dispensed by the number of months of follow-up in the first year of treatment. Adherence was categorized as 0%-<40%, 40%-<80%, 80%-<95%, and !95%.
Statistical analyses
Explanatory logistic and survival models (using Cox proportional hazard regression) were built to identify those factors most influential in the emergence of multiclass resistance. ''Event time'' was defined as the time the individuals developed multiclass resistance, and ''censoring time'' was defined as the time of the last resistance test (Web Table 2 ). Kaplan-Meier estimates were plotted to show the incidence of multiclass resistance over time, and the difference between groups was assessed by the log-rank test. The assumptions of proportional hazards were examined graphically. For the logistic model, the area under the receiver operating characteristic curve was used to measure the model's ability to discriminate between those with multiclass resistance and those without (19) . The selection of variables for both models was based on 2 criteria: the Akaike Information Criterion and type III P values. These 2 criteria balance the model choice on finding the best explanatory model (type III P values À lower P values indicates more significance) and at the same time a model with the best goodness-of-fit statistic (the Akaike Information Criterion À lower values indicates better fit). At each step of this process, the Akaike Information Criterion value and the type III P values of each variable are recorded, and the variable with the highest type III P value is dropped, until there are no more variables left in the model. The final model has the lowest Akaike Information Criterion (6). Categorical variables were compared by using the v 2 or Fisher's exact test, and continuous variables were compared by using the Wilcoxon rank-sum test. All reported P values are 2 sided. All analyses were performed by using SAS statistical software (version 9.1.3, service pack 3; SAS Institute, Inc., Cary, North Carolina). Table 3 ). The patients excluded consisted of 550 individuals (30% of the initial cohort of 1,820 patients) who were eligible for resistance testing but did not receive it, 294 who had viral load below the genotypic test threshold, 64 who had no follow-up, and 79 who had baseline resistance. The remaining individuals were mostly male (74%), with no history of injection drug use (67%) and a median age of 40 years (interquartile range (IQR), 34-47 years); when they started therapy (typically between 2000 and 2002; 82%), they mostly received a NNRTI-based regimen (50%), had a median viral load of 5.0 copies/mL (IQR, 4.8-5.0 copies/mL) and a median CD4 cell count of 220 cells/mm 3 (IQR, 110-350 cells/mm 3 ), had adherence in their first year of !95%, and did not change regimens until the emergence of multiclass resistance (69%). Of note, the excluded individuals differed from those in this study in gender (females, 85%); age Abbreviations: HAART, highly active antiretroviral therapy; NNRTI, nonnucleoside reverse transcriptase inhibitor; NS, not significant using the model selection strategy.
a Changes in viral load and in CD4 cell count are from baseline to the time of emergence of resistance (!2 classes) or censoring. ''Odds ratio'' refers to the logistic model estimating the probability of emergence of antiretroviral resistance to at least 2 classes; ''hazard ratio'' refers to the survival model estimating the hazard of emergence of antiretroviral resistance to at least 2 classes.
b -, confidence interval not estimated for reference category.
months), and for NRTI/NtRTI being 11 months (IQR, 4-21 months). Most individuals developed NRTI/NNRTI-type resistance (Table 1) . Individuals who were multiclass resistant were more likely to have a history of injection drug use, to have been first prescribed NNRTI-based regimens, and to have adherence between 80% and <95%, a smaller change in viral load since baseline, and a lower CD4 cell count at baseline (P < 0.01) ( Table 2 ). Of note, only 16 individuals developed resistance to all 3 classes of antiretroviral drugs (2% of all tested; incidence rate, 0.9 per 1,000 personmonths) during a median follow-up of 23 months (IQR, 8-41 months). Figure 1 illustrates the incidence rate of multiclass resistance by initial HAART regimen over time, which was consistently higher among those on NNRTIbased HAART regimens.
To better understand the results of the multivariate regression, we first examined the bivariate associations of change in viral load and CD4 cell count with history of injection drug use, initial HAART regimen, and adherence ( Figure 2 ). There was a steep negative gradient between adherence and change in viral load, with !95% adherent individuals more likely to experience superior virologic response in comparison with those in the other adherence strata; this association did not change when we further stratified the data by history of injection drug use. The gradient for CD4 cell change was also steep but positive, with individuals without injection drug use history also experiencing superior immunologic response. Individuals who received boosted protease inhibitor experienced greater immunologic and virologic response than individuals on other regimens, regardless of their history of injection drug use. Note that those receiving NNRTIs responded relatively poorly in both indicators. The association did not change when we further stratified the data by both history of injection drug use and adherence.
The product limit estimates of the cumulative probability of multiclass resistance at 12, 18, 24, and 36 months of follow-up were, respectively, 6.5% (6 0.1%), 12.3% (6 1.4%), 16.2% (6 1.6%), and 22.3% (6 1.9%). The Kaplan-Meier estimates, stratified by adherence, number of therapy changes, first HAART regimen, history of injection drug use, viral load change, and CD4 cell count change, are displayed in Web Figure 1 . At 12 months, the risk of developing resistance to !2 classes was the highest for those individuals with adherence between 80% and <95% (16.5%, 6 3.9%), who initiated therapy on NNRTIs (19.3%, 6 2.3%), who never changed therapy (17.6%, 6 2.1%), who experienced a change in viral load greater than À2 and less than or equal to À1 log 10 copies/mL (16.7%, 6 3.2%), and who experienced a change in CD4 cell count greater than À50 and less than 50 cells/mm 3 (20.9%, 6 2.9%). These estimates did not differ by history of injection drug use.
Subsequently, we fitted 2 multivariate explanatory models to assess which patient characteristics better explained the probability of, and the time to, multiclass resistance (Table 2 ). Those with a higher probability of multiclass resistance had a history of injection drug use (odds ratio (OR) ¼ 1.95, 95% confidence interval (CI): 1.28, 2.98), experienced a change in viral load greater than À2 and less than or equal to À1 log 10 copies/mL (OR ¼ 2.88, 95% CI: 1.40, 5.96) and greater than À1 and less than or equal to 0 log 10 copies/mL (OR ¼ 3.70, 95% CI: 1.81, 7.56), who initiated therapy on an unboosted protease inhibitor-(OR ¼ 4.36, 95% CI: 2.12, 8.97) or on a NNRTI-based HAART regimen (OR ¼ 5.67, 95% CI: 3.36, 9.59), those with adherence between 80% and less than 95% (OR ¼ 1.92, 95% CI: 1.09, 3.38), and those who changed therapy 2 or more times (OR ¼ 2.10, 95% CI: 1.08, 4.08). Older individuals (OR ¼ 0.96, 95% CI: 0.94, 0.98) were less prone to multiclass resistance.
The results for the multivariate survival analysis were very similar to the logistic regression results ( Table 2) . History of injection drug use was not selected for inclusion into the final model, and those who experienced a decrease in viral load of greater than À1 and less than or equal to 0 log 10 copies/mL were no longer at a higher risk of multiclass resistance. Change in the CD4 cell count became significant, with those with change between greater than À50 and less than 50 cells/mm 3 having a higher hazard of multiclass resistance than those with a higher positive change (hazard ratio (HR) ¼ 1.69, 95% CI: 1.18, 2.43). People changing therapy 1 or more times were less likely to experience multiclass resistance (1 time, HR ¼ 0.46, 95% CI: 0.29, 0.74; 2 or more times, HR ¼ 0.48, 95% CI: 0.29, 0.80) ( Table 2 ). These last hazard ratios are in the opposite direction in comparison with the odds ratio, which is, in part, attributed to the fact that the hazard ratios take into consideration the timing to develop multiclass resistance, and the odds ratio is only a probability regardless of when the person developed multiclass resistance. 
DISCUSSION
Our results demonstrate that 3-class antiretroviral drug resistance is very uncommon in our population-based cohort. Only 16 individuals who started HAART developed 3-class antiretroviral drug resistance during nearly 2 years of follow-up. In contrast, 2-class antiretroviral drug resistance was relatively common in our population-based cohort, as this was demonstrated in 17% of the tested individuals during a median follow-up of 14 months for an incidence rate of 0.8 cases per 1,000 person-months. Interestingly, we observed a dramatic decline in the incidence rate of antiretroviral drug resistance between 2000 and 2007, largely as a reflection of an increased rate of viral load suppression within the HAART Observational Medical Evaluation and Research Cohort (designated the ''HOMER'' Cohort), as reported elsewhere (15) . We observed that resistance to any of the 3 antiretroviral classes decreased from 23% to 10% between 2000 and 2007 within the HOMER Cohort. These results are consistent with those of Phillips et al. (11) from the United Kingdom Collaborative HIV Cohort. Within this cohort, the risk of developing mutations from at least 2 of the 3 main antiretroviral drug classes was 20% for the 933 individuals who had resistance testing done after 6 years of follow-up, and the probability of virologic rebound during the same period was estimated to be only 0.38 (95% CI: 0.35, 0.41).
Our results also showed that initial therapy is the stronger factor associated with the risk of emergence of multiclass resistance, with NNRTIs being the therapy mainly associated with the emergence of multiclass resistance. This observation is consistent with the results of clinical trials (20) , which have generally shown higher efficacy of NNRTIbased HAART when compared with boosted-protease inhibitor-based HAART, but greater frequency of drug resistance among those who develop virologic failure with NNRTI-versus protease inhibitor-based HAART. This is directly related to the low genetic barrier of first-generation NNRTIs (efavirenz and nevirapine) currently recommended for first-line therapy (13, (21) (22) (23) . Our results regarding the association of initial NNRTI-based HAART and higher likelihood of resistance cannot be necessarily construed as a reason to alter current therapeutic guidelines, which recommend NNRTI as a possible initial therapy, particularly efavirenz-based HAART (24) . NNRTI-based HAART has been for sometime the simplest of the HAART regimens available, as it requires fewer pills and it can be taken once a day without dietary restrictions. This may generate a potential indication bias as the NNRTI-based regimens may be preferentially offered to individuals who are perceived to have substantial adherence challenges (i.e., homelessness, addiction, mental illness, and so on). The potential interaction effect between adherence and HAART regimen is worth mentioning and should be further explored, but unfortunately, we don't have the power to assess this effect in our cohort. We also found that viral load decreases of less than 2 log 10 copies/mL and therapy changes were the next 2 most influential factors explaining multiclass resistance. These individuals were the ones most likely to have been on NNRTI-containing regimens, and they were also more likely to need therapy changes. These findings are consistent with those from a previous paper published by Harrigan et al. (25) , who also found that those with a higher baseline viral load and CD4 cell count and prescribed NNRTI in the initial HAART regimen were more likely to develop multiclass resistance, given that these individuals were the ones more likely to have adherence levels between 80% and 90%. The registry used to obtain our patients is the same as the one in the paper by Harrigan et al. (25) ; however, in the older paper, the cohort was older and the eligibility was to start HAART before 2000. The regimens currently used for our patients have also changed completely since 1999, now being less toxic and more tolerable. Also here, more individuals were tested by using a more recent version of the assay to detect drug resistance with a lower detection limit. Finally, here we looked at the accumulation of multiclass resistance, contrary to other papers from our group (2, 25) that looked at the presence of resistance in specific classes or in general.
Several features of this study are noteworthy. This study was based on individuals within a population-based HIV treatment program who had free access to medical care, antiretroviral therapy, and laboratory monitoring. Yet, a significant number of these individuals have not been monitored according to the program guidelines nor are accessing treatment (e.g., vulnerable and hard-to-reach individuals). Further efforts are needed to promote physicians' adherence to therapeutic guidelines, and further research is being conducted to reach these individuals and to engage them in care. Another unique feature is the complete data capture regarding adherence to therapy. The measure of adherence based on refill compliance is known to reflect the maximal adherence level; however, this has been shown to be highly predictive of virologic and immunologic responses, emergence of resistance, and survival (4, 6, 25) . Third, Figure 1 was based on the year of first HAART for each patient, and at the end of follow-up, we looked at how many patients developed multiclass resistance. Some might argue that survival bias could have played a role in explaining theses trends. However, we believe that this figure might also reflect the individual drugs in the HAART regimen, which in 2006 were much more tolerable and easy to take than in 2000, and the choice of first regimen by the physician, who preferred to start with NNRTIs in 2000 and in 2006 preferred to start with boosted protease inhibitor. Fourth, in this cohort only 46% of individuals were tested for drug resistance, which reflects the assay's sensitivity to detect drug resistance and the fact that not all physicians order resistance tests upon treatment failure or at baseline. Finally, although we adjusted our analyses for several demographic and clinical characteristics, as in all observational studies unmeasured differences may exist among study populations, and for this reason, our findings should be interpreted cautiously.
In conclusion, we have shown that 3-class antiretroviral drug resistance is very uncommon in our population-based cohort. In contrast, 2-class antiretroviral drug resistance was demonstrated in 17% of the cohort during a median followup of 14 months, with a steep decline in the incidence of antiretroviral drug resistance between 2000 and 2007. Our findings point toward an increased HAART efficacy over recent years. Initial NNRTI-based HAART, incomplete viral suppression, and remaining on failing therapy were associated with an increased likelihood of multiclass resistance; however, these findings do not necessarily imply that a revision in guidelines is required. Further monitoring will be needed to characterize the impact of newer drugs and drug classes active against drug-resistant HIV. On the basis of our findings and those from the literature available, priority should be given to emphasize the importance of viral load and resistance monitoring before starting HAART and upon virologic failure.
